vTv Therapeutics Inc. (VTVT)
Automate Your Wheel Strategy on VTVT
With Tiblio's Option Bot, you can configure your own wheel strategy including VTVT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTVT
- Rev/Share 0.0026
- Book/Share 1.3515
- PB 13.8556
- Debt/Equity 0.0158
- CurrentRatio 7.3948
- ROIC -0.7394
- MktCap 43628891.0
- FreeCF/Share -3.594
- PFCF -1.8441
- PE -5.8717
- Debt/Assets 0.0039
- DivYield 0
- ROE -1.4487
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time for the Company, which recently reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes …
Read More
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that screening has been reinitiated in the Company's CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment of type 1 diabetes (T1D).
Read More
About vTv Therapeutics Inc. (VTVT)
- IPO Date 2015-07-30
- Website https://www.vtvtherapeutics.com
- Industry Biotechnology
- CEO Mr. Paul J. Sekhri M.Sc.
- Employees 23